Summing up cancer stem cells | Nature
Chronic myeloid leukaemia is associated with the oncogene BCR-ABL. The tyrosine kinase inhibitor imatinib (Gleevec), in the news as the first molecularly targeted anticancer drug, acts by impairing the function of this oncogene. A study of 169 patients receiving imatinib followed the kinetics of BCR-ABL in order to develop a mathematical model of the in vivo kinetics of a cancer. Imatinib reduced the rate of leukaemic cell production, but did not appear to deplete a population of leukaemic stem cells. The model also indicates when multiple drug therapy might be more effective than imatinib alone.
News & Views Published: 29 June 2005 Cancer biology Brian J. P. Huntly1,2 & D. Gary Gilliland1,2 Nature volume 435, pages 1169–1170 (2005) Cite this article 2639 Accesses 108 Citations 6 Altmetric Metrics details Are current cancer drugs targeted at the wrong kinds of cells? A pioneering approach to the development of treatments uses a mathematical model to follow how different types of tumour cells respond to therapy. This is a preview of subscription content, access via your institution Access options Access through your institution Subscribe to this journal Receive 52 print…
saved by
related reading
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemianature.com
- Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangementsnature.com
- Data driven model discovery and interpretation for CAR T-cell killing using sparse identification and latent variablespmc.ncbi.nlm.nih.gov
- The current state of the art and future trends in RAS-targeted cancer therapiesnature.com
- A simple algebraic cancer equation: calculating how cancers may arise with normal mutation ratesbmccancer.biomedcentral.com
- The novel mechanism of lenalidomide activity - PMCncbi.nlm.nih.gov
- The blood cancer that became solvableworksinprogress.news
- ncponc_2005_169.inddbrb.nci.nih.gov
- Immunotherapy for Cancer - NCIcancer.gov
- Cancer cells educate natural killer cells to a metastasis-promoting cell state - PMCpmc.ncbi.nlm.nih.gov
- Arc Institute’s first virtual cell model: <span style="font-variant: small-caps">S<span style="font-weight: bolder">tate</span></span> | Arc Institutearcinstitute.org
- Targeting telomerase for cancer therapy | Oncogenenature.com